Squarepoint Ops LLC Has $6.89 Million Stock Holdings in Enovis Co. (NYSE:ENOV)

Squarepoint Ops LLC raised its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 231.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 157,006 shares of the company's stock after purchasing an additional 109,707 shares during the period. Squarepoint Ops LLC owned 0.28% of Enovis worth $6,889,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ENOV. Aster Capital Management DIFC Ltd bought a new position in shares of Enovis in the fourth quarter valued at approximately $29,000. Quadrant Capital Group LLC boosted its holdings in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares in the last quarter. Quarry LP boosted its holdings in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 749 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in shares of Enovis by 56.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock valued at $143,000 after acquiring an additional 1,173 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ENOV has been the subject of several recent research reports. JMP Securities cut their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group cut their target price on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC cut their target price on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Enovis currently has an average rating of "Moderate Buy" and an average price target of $58.00.

Enovis Price Performance

ENOV stock traded down $0.42 on Friday, hitting $31.63. 132,526 shares of the company's stock traded hands, compared to its average volume of 791,878. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $51.00. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -14.43 and a beta of 1.79. The stock has a fifty day moving average of $34.16 and a 200-day moving average of $40.70. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. During the same quarter last year, the business posted $0.50 EPS. The company's revenue was up 8.2% on a year-over-year basis. On average, analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.